Virpax (VRPX) names Vinay Shah CFO; Christopher Chipman resigns

Virpax Pharmaceuticals, Inc.

Vinay Shah appointed CFO effective June 20, 2023, succeeding Christopher Chipman who resigned to pursue other opportunities.
Shah's base salary $312,000; target bonus 30% of base; option to purchase 100,000 shares vesting over 4 years.
Chipman's separation: $234,000 severance in 4 monthly installments of $58,500; COBRA for 4 months; accelerated option vesting.
Chipman's resignation not due to any disagreement with the company on operations, policies, or accounting.
Shah previously served as CFO of Aravive and held finance roles at Pacira Pharmaceuticals; over 30 years of experience.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Christopher Chipman

Chief Financial Officer

Virpax Pharmaceuticals, Inc.

Effective: 2023-06-30
Successor: Vinay Shah
Filed: June 21, 2023, 7:59 PM ET

On June 18, 2023, Christopher Chipman notified the Chairman of the Board of Directors of the Company of his decision to resign from his position as the Company’s Chief Financial Officer to pursue other opportunities.

Appointed

Vinay Shah

Chief Financial Officer

Virpax Pharmaceuticals, Inc.

Effective: 2023-06-20
Filed: June 21, 2023, 7:59 PM ET

Effective as of June 20, 2023, the Board of Directors of Virpax Pharmaceuticals, Inc. (the “Company”) appointed Vinay Shah to serve as the Company’s Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher Chipman resigned as Chief Financial Officer at Virpax Pharmaceuticals, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On June 18, 2023, Christopher Chipman notified the Chairman of the Board of Directors of the Company of his decision to resign from his position as the Company’s Chief Financial Officer to pursue other opportunities.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Vinay Shah was appointed as Chief Financial Officer at Virpax Pharmaceuticals, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

Effective as of June 20, 2023, the Board of Directors of Virpax Pharmaceuticals, Inc. (the “Company”) appointed Vinay Shah to serve as the Company’s Chief Financial Officer.

View on SEC.gov

Source: SEC EDGAR

accession 0001213900-23-050508

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.